financetom
Business
financetom
/
Business
/
Foxconn forecasts strong Q1 revenue after Q4 profit miss
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Foxconn forecasts strong Q1 revenue after Q4 profit miss
Mar 14, 2025 12:41 AM

TAIPEI (Reuters) -Taiwan's Foxconn, the world's largest contract electronics maker, forecast strong revenue growth in the first quarter after reporting a surprise 13% drop in fourth-quarter profit.

Foxconn, whose businesses include manufacturing iPhones for Apple ( AAPL ) and artificial intelligence servers for Nvidia ( NVDA ), booked October-December net profit of T$46.33 billion ($1.41 billion), missing the T$54.4 billion average of 15 analyst estimates compiled by LSEG.

The decline was Foxconn's first since the second quarter of 2023 when it fell 0.9%. Foxconn did not elaborate on its performance ahead of an earnings call at 3 p.m. (0700 GMT).

In January, Foxconn said October-December revenue jumped 15.2% to a record for that quarter on strong AI server sales.

The company, formally Hon Hai Precision Industry ( HNHPF ), on Friday said first-quarter revenue from consumer electronics is likely to grow significantly and that sales from cloud and networking products would grow strongly, without giving numerical guidance.

An escalating global trade war has complicated prospects as Foxconn has a major manufacturing presence in China and Mexico, two of the biggest U.S. trading partners facing increased import tariffs under the administration of U.S. President Donald Trump.

Apple ( AAPL ) said last month it will work with Foxconn to build a 250,000 square foot (23,200 square metre) facility in Houston to assemble servers for data centres that power Apple Intelligence.

Foxconn's share price has fallen 8.7% this year, hit by concern about the impact of U.S. tariffs and trade policy.

($1 = 32.9550 Taiwan dollars)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children
Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children
Apr 29, 2024
11:19 AM EDT, 04/29/2024 (MT Newswires) -- Aquestive Therapeutics ( AQST ) said Monday that the US Food and Drug Administration has approved Libervant Buccal Film to treat intermittent, stereotypic episodes of frequent seizure activity, which are distinct from a patient's usual seizure pattern, in epileptic patients aged 2 years to 5 years old. Aquestive Chief Executive Officer Daniel Barber...
L'Occitane's billionaire owner Geiger to take firm private in $1.8 bln deal
L'Occitane's billionaire owner Geiger to take firm private in $1.8 bln deal
Apr 29, 2024
April 29 (Reuters) - Hong Kong-listed L'Occitane International's chairman and controlling shareholder will take the French skin-care firm private, valuing it at a maximum of HK$13.91 billion ($1.78 billion), the company said on Monday. Reuters reported in early April that L'Occitane's Chairman Reinold Geiger was in advanced talks with investors and lenders about the deal, with U.S. private equity giant...
Update: Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Update: Sight Sciences Says it Obtained $34 Million Patent Infringement Verdict Against Alcon -- Shares Jump
Apr 29, 2024
11:21 AM EDT, 04/29/2024 (MT Newswires) -- (Updates with Alcon's ( ALC ) reply in the fourth paragraph and current stock movement in the fifth paragraph.) Sight Sciences ( SGHT ) said Monday it has received a jury trial verdict of $34 million related to the patent-infringement case it filed in September 2021 against Alcon ( ALC ) in the...
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome
Apr 29, 2024
11:19 AM EDT, 04/29/2024 (MT Newswires) -- X4 Pharmaceuticals ( XFOR ) said Monday that the US Food and Drug Administration has approved Xolremdi for use in patients 12 years and older with warts, hypogammaglobulinemia, infections and myelokathexis, or WHIM, syndrome to raise circulating mature neutrophils and lymphocytes. The approval was based on results of a late-stage trial that showed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved